-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EezXWCpzpI9U/TdsrxJuvuOp5hm4LeW+DTkI4aw3QCaPFr3wn9eqKhTeQN0550dF dlS2wLg7gFmQlWzZq1AlRQ== 0000062391-99-000003.txt : 19990507 0000062391-99-000003.hdr.sgml : 19990507 ACCESSION NUMBER: 0000062391-99-000003 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990506 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-48751 FILM NUMBER: 99612660 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 2: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G/A 1 AMENDMENT NO. 1 TO SCHEDULE 13-G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 04033A 10 0 ----------------- (CUSIP Number) =========================================================================== Page 1 of 9 Exhibit Index is located at page 9 2 CUSIP No. 04033A 10 0 - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Hoechst Marion Roussel, Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 3,004,436 Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 3,004,436 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 3,004,436 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 12.10% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 3 CUSIP No. 04033A 10 0 13G - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 3,004,436 Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 3,004,436 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 3,004,436 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 12.10% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 4 CUSIP No. 04033A 10 0 13G This Amendment No. 1 to the Statement on Schedule 13G of Hoechst Marion Roussel, Inc., a Delaware corporation, and HMR Pharma, Inc., a Delaware corporation, is filed to report the acquisition of an additional 478,120 shares of Series B Convertible Preferred Stock of Ariad Pharmaceuticals, Inc. (the "Issuer"). The Statement on Schedule 13G is hereby amended to read as follows: ITEM 1(a). NAME OF ISSUER: - ---------- --------------- Ariad Pharmaceuticals Inc. ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: - ---------- ------------------------------------------------ 26 Landsdowne Street Cambridge, MA 02139 ITEM 2(a). NAME OF PERSON FILING: - ---------- ---------------------- Hoechst Marion Roussel, Inc. HMR Pharma, Inc. Hoechst Marion Roussel, Inc., the record owner of the securities to which this Schedule relates, is owned 98.2% by HMR Pharma, Inc., and 1.8% by Hoechst Marion Roussel, S.A., a French corporation, both of which are wholly-owned subsidiaries of Hoechst Marion Roussel Aktiengesellschaft, a German corporation ("HMR AG"), which itself is a wholly-owned subsidiary of Hoechst Aktiengesellschaft, a publicly-held German corporation ("Hoechst AG"). Hoechst AG and HMR AG disclaim beneficial ownership of securities held by HMRI. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ---------- ------------------------------------------------------------ Hoechst Marion Roussel, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - ---------- ------------ Delaware As To Both Hoechst Marion Roussel, Inc. And HMR Pharma, Inc. ITEM 2(d). TITLE OF CLASS OF SECURITIES: - ---------- ----------------------------- Common Stock, $.001 Par Value 5 CUSIP No. 04033A 10 0 13G ITEM 2(e): CUSIP NUMBER: - ---------- ------------- 04033A 10 0 ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR 13D-2(b) or (c): - ------- ------------------------------------------------------- Not Applicable ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: As Of 01/01/99 3,004,436 Shares Of Series B Convertible Preferred Stock. The Shares Are Convertible Into Common Stock On A Share-For-Share Basis. (b): PERCENT OF CLASS: 12.10% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 3,004,436 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the 3,004,436 disposition of: (iv) Shared power to dispose or to direct the 0 disposition of: ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS - ------- --------------------------------------------- Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. - ------- ---------------------------------------------------------------- Not Applicable 6 CUSIP No. 04033A 10 0 13G ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH - ------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY --------------------------------------------------------------- Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP - ------- --------------------------------------------------------- Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. - ------- ------------------------------- Not Applicable ITEM 10. CERTIFICATION. - -------- -------------- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 7 CUSIP No. 04033A 10 0 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. May 6, 1999 --------------------------------- (Date) HMR PHARMA, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 8 CUSIP No. 04033A 10 0 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. May 6, 1999 --------------------------------- (Date) HOECHST MARION ROUSSEL, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 9 CUSIP No. 04033A 10 0 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated March 17, 1998, by and between Hoechst Marion Roussel, Inc. and HMR Pharma, Inc. (Incorporated by reference to the Statement on Schedule 13G filed by Hoechst Marion Roussel, Inc. and HMR Pharma, Inc. on March 31, 1998). -----END PRIVACY-ENHANCED MESSAGE-----